Besifloxacin-eluting contact lens with sustained drug delivery and enhanced bioavailability
International Journal of Pharmaceutics: X · 2026-06 · 11 · 100511
DOI: 10.1016/j.ijpx.2026.100511 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutics: X, 2026-06. Verfasst von Liangju Kuang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Bacterial keratitis is a prevalent and sight-threatening ocular infection. Current treatments typically involve intensive antibiotic eye drops or ointments; however, their effectiveness is limited by poor corneal penetration, low bioavailability, and suboptimal patient adherence. These limitations are particularly pronounced for besifloxacin, a fourth-generation fluoroquinolone with broad-spectrum antibacterial activity but low octanol-water partition coefficient and poor aqueous solubility. Here, we present a besifloxacin-eluting contact lens (BXF-CL) engineered to enhance corneal drug penetration and sustain therapeutic antibiotic levels. BXF-CLs were fabricated by encapsulating a thin, drug-loaded polymer film-composed of physiologically inert polymers (ethylcellulose and Eudragit® RSPO)-within the periphery of soft contact lenses via UV polymerization. The resulting lenses showed key physical properties comparable to commercial contact lenses, including morphology, water content, and light transmittance. In vitro and in vivo studies demonstrated sustained antibiotic release at clinically relevant levels for over 24 h. Furthermore, BXF-CLs maintained stable drug release and lens properties following terminal sterilization and two years of storage. Pharmacokinetic studies in rabbits revealed markedly enhanced intraocular delivery, achieving up to a 21.6-fold higher peak concentration in the aqueous humor compared with hourly besifloxacin eye drops. The eluted drug retained potent antimicrobial activity against both Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria in agar disk diffusion assays. Biocompatibility was confirmed by in vitro cytotoxicity and in vivo ocular irritation tests. Collectively, these results identify BXF-CL as a promising platform for sustained topical antibiotic delivery and improved management of bacterial keratitis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA, United States.
- The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Vision Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
- Laboratory for Biomaterials and Drug Delivery, Department of Anesthesiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.
Förderung
- National Institutes of Health
Zitieren
APA
Kuang, L., Boychev, N., Chen, L., Ross, A. E., Kanu, L. N., Miura, M., Peng, C., Yung, A., Yeung, V., Romanowski, E. G., Dana, R., Kohane, D. S., & Ciolino, J. B. (2026). Besifloxacin-eluting contact lens with sustained drug delivery and enhanced bioavailability. International Journal of Pharmaceutics: X, 11, 100511. https://doi.org/10.1016/j.ijpx.2026.100511
Vancouver
Kuang L, Boychev N, Chen L, Ross AE, Kanu LN, Miura M, et al. Besifloxacin-eluting contact lens with sustained drug delivery and enhanced bioavailability. International Journal of Pharmaceutics: X. 2026;11:100511. doi:10.1016/j.ijpx.2026.100511
BibTeX
@article{Kuang2026,
author = {Kuang, Liangju and Boychev, Nikolay and Chen, Lin and Ross, Amy E and Kanu, Levi N and Miura, Maria and Peng, Cheng and Yung, Ann and Yeung, Vincent and Romanowski, Eric G and Dana, Reza and Kohane, Daniel S and Ciolino, Joseph B},
title = {Besifloxacin-eluting contact lens with sustained drug delivery and enhanced bioavailability},
journal = {International Journal of Pharmaceutics: X},
year = {2026},
volume = {11},
pages = {100511},
doi = {10.1016/j.ijpx.2026.100511}
}
EUVIMED